Cytokine Signalling Forum

Publications





July 21

Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

Solipuram V, Mohan A, Patel R, Ni R.
Auto Immun Highlights. 2021;12(1):8.

The combination of JAK inhibitors with MTX is not associated with an increased risk of malignancy when compared to MTX alone. Although long-term studies are needed to confirm this conclusion from short-term studies. Although it is now known that patients with RA are predisposed to an increased risk of malignancy, especially malignant lymphomas, lung cancers and non-melanoma skin cancer, it remains unclear whether the combination therapy is associated with a higher risk. To this end, Solipuram...

October 20

Eficácia de Baricitinib no Tratamento de Artrite Reumatoide: Efeito Modulatório em Biomarcadores Inflamatórios e de Fibrose em Circunstâncias de Vida Real

Alessandro M, Perillo F, Refini R, Bergantini L, Bellisai F, Selvi E, Cameli P, Manganelli S, Conticini E, Cantarini L, Sestini P, Frediani B, Bargagli E.
Int Immunopharmacol. 2020 Sep;86:106748.

BARI demonstrated to be a safe immune modulator that reduces the concentrations biomarkers of lung fibrosis and inflammation in RA patients, including a subgroup with interstitial lung involvement. Professor Alessandro and colleagues analysed the effects of baricitinib in a population of RA and RA-ILD patients in a real-life setting, describing any changes in lung function parameters, serum inflammatory biomarkers and fibrotic biomarkers after 6 months of treatment. Fifteen patients were recru...

Keywords: JAK, Baricitinib, Clinical, Efficacy

Translated by: Igor Kos